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Efficacy and Safety of Intravitreal Aflibercept 
Treat-and-Extend for Macular Edema in Central 
Retinal Vein Occlusion: the CENTERA Study 
JEAN-FRANÇOIS KOROBELNIK, MICHAEL LARSEN, NICOLE ETER, CLARE BAILEY, SEBASTIAN WOLF, 
THOMAS SCHMELTER, HELMUT ALLMEIER, AND VARUN CHAUDHARY 
• PURPOSE: To evaluate the efficacy and safety of intrav- 
itreal aflibercept (IVT-AFL) treat-and-extend dosing in 
patients with macular edema secondary to central retinal 
vein occlusion (CRVO). 
• DESIGN: CENTERA (Evaluation of a Treat and Ex- 
tend Regimen of Intravitreal Aflibercept for Macular 
Edema Secondary to CRVO; NCT02800642) was an 
open-label, Phase 4 clinical study. 
• METHODS: Patients received 2 mg of IVT-AFL at base- 
line and every 4 weeks thereafter, until disease stability 
criteria were met (or until week 20), at which point treat- 
ment intervals were adjusted in 2-week increments based 
on functional and anatomic outcomes. 
• RESULTS: From baseline to week 76, 105 patients 
(65.6%) ( P < .0001 [test against threshold of 40%]) 
gained ≥15 letters; and, during the treat-and-extend 
phase, 72 patients (45.0%) ( P = 0.8822 [test against 
threshold of 50%]) achieved a mean treatment interval 
of ≥8 weeks. A last and next planned treatment inter- 
val of ≥8 weeks was achieved by 101 patients (63.1%) 
and by 108 patients (67.5%), respectively. Mean ± SD 
best-corrected visual acuity increased from 51.9 ± 16.8 
letters at baseline to 72.3 ± 18.5 letters at week 76 (mean 
change: + 20.3 ± 19.5 letters), and central retinal thick- 
ness decreased from 759.9 ± 246.0 µm at baseline to 
265.4 ± 57.9 µm at week 76 (mean change: −496.1 ±
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252.4 µm). The safety profile of IVT-AFL was consistent 
with that of previous studies. 
• CONCLUSIONS: Clinically meaningful improvements 
in functional and anatomic outcomes were achieved 
with IVT-AFL treat-and-extend dosing. Most patients 
achieved a last actual and last intended treatment in- 
terval of ≥8 weeks; therefore, treatment intervals may 
have been extended even further with a longer study 
duration. (Am J Ophthalmol 2021;227: 106–115. 
© 2021 The Author(s). Published by Elsevier Inc. 
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( HTTP://CREATIVECOMMONS.ORG/LRetinal vein occlusion is a common cause of vision loss
n patients with chronic macular edema. 1 There are 3 dif-
erent types of retinal vein occlusions, based on the obstruc-
ion site: branch retinal vein occlusion, central retinal vein
cclusion (CRVO), and hemiretinal vein occlusion. 2 
RVO is an obstruction of the main retinal vein at or poste-
ior to the optic nerve head 3 ; it affects both men and women
nd occurs most commonly in patients who are 60 years of
ge or older. 2 , 4 Although CRVO is usually unilateral, 4 ap-
roximately 7.8% of patients with CRVO in one eye also
ave RVO in the fellow eye. 5 CRVO leads to impaired ve-
ous drainage from the eye, which in turn may result in
ncreased venous pressure, reduced arterial perfusion, and
etinal ischemia. Retinal nonperfusion leads to an increase
n vascular endothelial growth factor (VEGF), which in-
reases vascular permeability and can cause macular edema,
etinal hemorrhage, and neovascularization. 6 
Treatment of macular edema secondary to CRVO in-
olves the administration of anti-VEGF agents, such as
flibercept and ranibizumab, which have become the stan-
ard of care. The efficacy and safety of intravitreal afliber-
ept (IVT-AFL) were assessed in 2 pivotal Phase 3 stud-
es, COPERNICUS (NCT00943072) 7 , 8 and GALILEO
Vascular Endothelial Growth Factor [VEGF] Trap-Eye: In-
estigation of Efficacy and Safety in Central Retinal Vein
cclusion; NCT01012973), 9 , 10 in which findings demon-ISHED BY ELSEVIER INC. 








































































































or second to last visit and no more than a 5-letter loss from strated that IVT-AFL was beneficial for the treatment of
macular edema secondary to CRVO. In these studies, the
mean change from baseline to week 24 in best-corrected
visual acuity (BCVA) was + 17.3 and + 18.0 letters for
patients treated with IVT-AFL compared with −4.0 and
+ 3.3 letters in patients who received sham injections, re-
spectively. 7 , 10 These studies demonstrate how, if left un-
treated, patients with macular edema secondary to CRVO
lose VA and have a poor prognosis. This was similarly
shown in the CRUISE study (A Study of the Efficacy and
Safety of Ranibizumab Injection in Patients With Mac-
ular Edema Secondary to Central Retinal Vein Occlu-
sion; NCT00485836), in which mean change from base-
line BCVA at month 6 was + 12.7 letters and + 14.9 letters
in the 0.3-mg and 0.5-mg ranibizumab groups, respectively,
and + 0.8 letters in the sham group. 11 Both the COPER-
NICUS and the GALILEO studies included pro re nata
(PRN) dosing from week 24 of treatment to investigate
the possibility of extending the treatment interval beyond
4 weeks. Post hoc assessment of the different dosing sub-
groups demonstrated some de-stabilization of the disease
with doses administered PRN. Although the deterioration
seen during the study period was minor, possibly due to the
regular monitoring schedule implemented in those trials,
it is likely to progress over the expected longer-term treat-
ment duration required in the real-world setting for patients
with macular edema secondary to CRVO. 
The Lucentis, Eylea, Avastin in Vein Occlusion
(LEAVO) study (ISRCTN13623634) compared IVT-
AFL, bevacizumab, and ranibizumab using a PRN dosing
regimen and introduced a threshold of treatment success
for suspending treatment ( > 83 Early Treatment Diabetic
Retinopathy Study [ETDRS] letters), which allowed a
comparative assessment of the treatment burden associated
with each treatment arm. 12 Treatment with any of these
3 anti-VEGF agents resulted in improved and sustained
VA when patients were monitored regularly and treated
promptly (IVT-AFL: + 15.1 letters; ranibizumab: + 12.5 let-
ters; and bevacizumab: + 9.8 letters at week 100). Notably,
IVT-AFL was non-inferior to ranibizumab at week 100. 
Post hoc analyses of COPERNICUS and GALILEO sup-
ported the implementation of proactive treatment to pre-
vent deterioration of functional and anatomic outcomes.
“Treat and extend” is a proactive, individualized dose strat-
egy whereby the patient receives an injection at every visit.
The treatment interval is decided at every visit and is gradu-
ally extended if functional and anatomic stability are main-
tained and shortened if deterioration is observed, to mini-
mize the risk of disease recurrence rather than in response to
it. 13 Additionally, with treat-and-extend dosing regimens,
the need for interim monitoring is minimized, which re-
duces the number of appointments per patient and mini-
mizes the need for monitoring visits. 14 Decreasing the num-
ber of visits per patient reduces the treatment burden and
the need for scheduling visits, thus benefiting both the pa-
tient and the health care providers. VOL. 227 XXXTo our knowledge, treat-and-extend dosing regimens
ave not been evaluated in large-scale studies of IVT-AFL
or the treatment of macular edema secondary to CRVO.
herefore, the aim of the CENTERA (Evaluation of a Treat
nd Extend Regimen of Intravitreal Aflibercept for Macu-
ar Edema Secondary to CRVO; NCT02800642) study was
o assess the efficacy and safety of IVT-AFL administered in
 treat-and-extend dosing regimen in patients with macular
dema secondary to CRVO. 
METHODS 
STUDY DESIGN: CENTERA (NCT02800642) was a 76-
eek, multicenter, open-label, single-arm, Phase 4 study
hat assessed the efficacy and safety of IVT-AFL adminis-
ered using a treat-and-extend dosing regimen in treatment-
aive patients with macular edema secondary to CRVO.
ENTERA was conducted between June 2016 and July
019 at 42 study centers in Australia, Canada, Denmark,
rance, Germany, Italy, Spain, and the UK, in accordance
ith the Declaration of Helsinki and the International
ouncil for Harmonisation guideline E6: Good Clinical
ractice. The protocol and any amendments were reviewed
nd approved by each study site’s Independent Ethics Com-
ittee or Institutional Review Board (IRB) before the start
f the study. The name of each study site’s IRB is listed in
upplemental Table 1. All enrolled patients provided writ-
en informed consent. 
PARTICIPANTS: Treatment-naive patients ≥18 years of
ge with center-involved macular edema secondary to
RVO for no longer than 3 months were enrolled. Patients
ere required to have a BCVA of 73-24 ETDRS letters
Snellen equivalent of 20/40-20/320) in the study eye. All
atients were scheduled to be treated with IVT-AFL as part
f routine clinical practice, with the intent to use a treat-
nd-extend regimen after the initial dose. Exclusion criteria
re listed in the Supplemental material. 
INTERVENTIONS: CENTERA was a single-arm study,
nd patients received treatment at the discretion of the
hysician. All patients received 2-mg IVT-AFL injections
t baseline and every 4 weeks until disease stability crite-
ia were met or until week 20, whichever occurred first (the
nitiation phase of the treatment). Starting at week 8, the
e-treatment interval was determined, and the frequency of
njections could be adjusted by 2-week increments to main-
ain stable functional and anatomic outcomes (the treat-
nd-extend phase of treatment). 
The stability criteria were no new cysts found on optical
oherence tomography; BCVA within a ±5-letter “stability
orridor” (defined as no more than a 5-letter gain as the lastXXX 107 
FIGURE 1. Patient disposition. Two patients had no post-baseline assessments available and were not included in the full analysis 




















































5  best previous BCVA at any visit); and central retinal thick-
ness (CRT) within a ±20% “stability corridor” (defined as
no more than 20% thickness reduction as the last or second
to last visit and no more than 20% thickening from best pre-
vious CRT at any visit). Values of BCVA and CRT outside
those “stability corridors” were considered “improvements”
for higher BCVA values and lower CRT values and “dete-
riorations” for lower BCVA values and higher CRT values.
From week 8, at every treatment visit (and at weeks 24,
52, and 76), the physician determined the stability status
of each patient, and the following algorithm was used to
determine the re-treatment interval: if the condition was
stable (all stability criteria met), the treatment interval was
extended by 2 weeks. If the condition was improving (no
new cysts and improvement in at least 1 of the disease ac-
tivity criteria [BCVA or CRT] with the other improving or
stable), the treatment interval was maintained; and if the
condition was deteriorating (new cysts and/or deterioration
in at least 1 of the other disease activity criteria [BCVA or
CRT]), the treatment interval was reduced by 2 weeks. In-
jections were not to be administered more frequently than
every 4 weeks (minimum re-treatment interval). 
• STUDY ENDPOINTS: The pre-determined co-primary
endpoints were the proportion of patients who gained ≥15
letters from baseline to week 76 and the proportion of pa-
tients with a mean treatment interval of ≥8 weeks from the
last initiation phase visit to week 76. These endpoints were108 AMERICAN JOURNAL OF OPHTet if significantly ≥40% of patients gained ≥15 letters and
f significantly ≥50% of patients had a mean treatment in-
erval of ≥8 weeks. 
Secondary endpoints included mean change in BCVA
nd CRT from baseline to weeks 24, 52, and 76; the num-
er of injections from baseline to week 76; and the mean
reatment interval from baseline to week 76. Other end-
oints reported included the proportion of patients who lost
 15 letters. The following post hoc analyses were also con-
ucted: the proportion of patients who achieved a last ac-
ual (defined as the length of the interval before study end
last]) and last intended treatment interval (defined as the
ext planned interval [next planned]) of ≥8 weeks and the
roportion of patients who had a BCVA of ≥70 letters at
ll mandatory study visits. Safety was assessed throughout
he study period. Adverse events (AEs) were treatment-
mergent if they occurred or worsened after the first IVT-
FL dose and, at most, 30 days after the last dose. All AEs
ere reported in case report forms and coded using Medi-
al Dictionary for Regulatory Activities, edition 22.0. An
djudication of AEs according to the Antiplatelet Trialists’
ollaboration criteria was also performed. 
STATISTICAL ANALYSIS: Study success required that a
ain of ≥15 letters at week 76 was reached by significantly
ore than 40% of patients and that a mean treatment in-
erval of ≥8 weeks was reached by significantly more than


































































































related to IVT-AFL. act 1-sample binomial test was used to assess each of the co-
primary efficacy variables at a significance level of 5% (2-
sided test) using the full analysis set (FAS), and 95% con-
fidence intervals (CIs) were provided. A sample size of 150
patients was calculated to provide a power of ≥90% to meet
both co-primary endpoints, assuming a true probability for
gaining ≥15 letters of 55% and a true probability to reach
a mean treatment interval of ≥8 weeks of 65%. All other
variables were analyzed by descriptive statistical methods,
and frequency tables were generated for categorical data. 
The safety analysis set included all enrolled patients who
received IVT-AFL. The FAS included all enrolled patients
who received IVT-AFL, had a baseline BCVA assessment,
and had at least 1 post-baseline BCVA assessment. The
primary efficacy analysis was conducted using the FAS.
The per-protocol set (PPS) included all enrolled patients
who received IVT-AFL, had a BCVA assessment at study
baseline, had at least 1 BCVA assessment at week 24 or
later, and did not have a major protocol deviation. The co-
primary efficacy variable sensitivity analysis was conducted
using the PPS. Statistical evaluation was performed using
Statistical Analysis System version 9.4 software (SAS In-
stitute, Cary, North Carolina, USA). 
RESULTS 
• PATIENTS: Of the 244 patients who were enrolled, 162
completed screening and entered the treatment period.
Two patients had no post-baseline assessments available
and were not included in the FAS. Overall, 150 patients
(92.6%) completed the study. The reasons for study dis-
continuation were death (n = 4), withdrawal by patient
(n = 3), AEs (n = 2), physician decision (n = 2), and lost
to follow-up (n = 1). In total, 147 patients were included
in the PPS ( Figure 1 ). 
The overall mean ± SD age was 66.2 ± 13.4 years, and
60.0% of patients were male ( Table 1 ). At baseline, mean
± SD BCVA was 51.9 ± 16.9 letters and CRT was 759.9 ±
246.0 µm. 
• TREATMENT EXPOSURE: Patients received a mean 5.3 ±
0.7 (baseline to week 24), 3.9 ± 1.3 (weeks 24-52), and
3.0 ± 1.3 (weeks 52-76) IVT-AFL injections. Of those who
completed treatment (n = 150), the mean treatment inter-
val in the treat-and-extend phase was 7.6 ± 1.9 weeks, and
the mean length of the last and next planned treatment in-
tervals were 9.3 ± 3.5 weeks and 9.7 ± 3.8 weeks, respec-
tively. Overall, 25.6% (n = 41) and 36.9% (n = 59) of pa-
tients achieved a last and a next planned treatment interval
of ≥12 weeks, respectively. 
• EFFICACY: In total, 105 patients (65.6%; 95% CI, 57.7-
72.9; P < .0001 [test against threshold of 40%]) gained
≥15 letters from baseline to week 76. Overall, 72 patients
(45.0%; 95% CI, 37.1-53.1; P = .8822 [test against thresh-VOL. 227 XXXld of 50%]) achieved a mean treatment interval of ≥8
eeks during the treat-and-extend phase. Additionally, 101
atients (63.1%) achieved a last and 108 patients (67.5%)
chieved a next planned treatment interval of ≥8 weeks. 
A sensitivity analysis of the coprimary efficacy variables
onducted using the PPS provided results similar to the
rimary analysis of the FAS: 98 patients (66.7%; 95% CI,
8.4-74.2) gained ≥15 letters from baseline to week 76 and
0 patients (47.6%; 95% CI, 39.3–56.0) achieved a mean
reatment interval of ≥8 weeks during the treat-and-extend
hase. 
Clinically meaningful improvements in mean BCVA
ere observed at all mandatory visits. Mean ± SD BCVA
as 51.9 ± 16.8 letters at baseline and 72.3 ± 18.5 letters
t week 76 (mean change: + 20.3 ± 19.5 letters) ( Figure 2 ).
Overall, 112 patients (70.0% gained ≥15 letters, and 153
atients (95.6%) maintained vision ( < 15 letters loss) from
aseline to week 76 in the FAS (last observation carried
orward). Categorical BCVA gains and losses from baseline
o week 76 are shown in Supplemental Figure 1. 
In a post hoc analysis of the FAS, 22 patients (13.8%)
ad a baseline BCVA of ≥70 letters (20/40 Snellen equiv-
lent), which increased to 107 patients (66.9%) at week
6 (last observation carried forward). Overall, 96 patients
60.0%) included in the FAS had a BCVA of ≥70 letters at
ll mandatory study visits (weeks 24, 52, and 76). 
Clinically meaningful improvements in mean CRT
ere observed at all mandatory visits. Mean ± SD CRT
ecreased from 759.9 ± 246.0 µm at baseline to 265.4 ±
7.9 µm at week 76 (mean change: −496.1 ± 252.4 µm)
 Figure 3 ). 
SAFETY: In total, 131 patients (80.9%) reported at least
 treatment-emergent AEs (TEAEs) during the study, and
hese TEAEs were predominantly mild or moderate in
everity ( Table 2 ). Overall, 90 patients (55.6%) reported
cular TEAEs in the study eye, the most common of which
ere reduced VA (24 patients; 14.8%), increased intraoc-
lar pressure (20 patients; 12.3%), conjunctival hemor-
hage (15 patients; 9.3%), and retinal ischemia (15 pa-
ients; 9.3%). No cases of endophthalmitis were reported.
 listing of ocular TEAEs ≥1% in the study eye is reported
n Supplemental Table 2. 
Serious TEAEs were reported in 32 patients (19.8%),
nd 8 patients (4.9%) experienced serious ocular TEAEs
n the study eye. One case of intraocular inflammation,
ridocyclitis, and 1 case of retinal artery occlusion (0.6%
ach) were assessed as serious TEAEs related to IVT-AFL.
n total, there were 4 deaths reported; one patient had
n Antiplatelet Trialists’ Collaboration event (pulmonary
mbolism; the patient also experienced a lower respiratory
ract infection and atrial flutter). The other 3 deaths
eportedly were due to B-cell lymphoma, intestinal per-
oration, and pneumonia (n = 1 each). Two deaths were
reatment-emergent, and none were assessed as beingXXX 109 
TABLE 1. Patient Baseline Demographics and Disease 
Characteristics 
Characteristic IVT-AFLN = 160 
Mean age, years (SD) 66.2 (13.4) 
Age range, years, n (%) 
18–64 62 (38.8) 
65–84 87 (54.4) 
≥85 11 (6.9) 
Sex, n (%) 
Male 96 (60.0) 
Race, n (%) 
White 152 (95.0) 
Asian 3 (1.9) 
Black 1 (0.6) 
Not reported 4 (2.5) 
Mean BVCA ETDRS letters, (SD) 51.9 (16.9) 
Mean CRT, µm (SD) a 759.9 (246.0) 
Weeks since CRVO diagnosis, n (%) b 
0 3 (1.9) 
1 35 (22.3) 
2 43 (27.4) 
3 21 (13.4) 
4 13 (8.3) 
5 8 (5.1) 
6 9 (5.7) 
7 5 (3.2) 
8 3 (1.9) 
9 3 (1.9) 
≥10 17 (10.8) 
Mean refraction sphere, diopters (SD) 1.8 (1.7) 
Capillary non-perfusion on FA, n (%) 
No 149 (93.1) 
Yes 11 (6.9) 
Location of capillary non-perfusion on FA, n (%) 
Q1, Q2, Q3, Q4 6 (3.8) 
Q2, Q3 3 (1.9) 
Q3 2 (1.3) 
Gonioscopy, n (%) 
Normal 148 (92.5) 
Abnormal 9 (5.6) 
Missing 3 (1.9) 
a n = 158 
b n = 157. 
Full analysis set. BVCA = best-corrected visual acuity; CRT = central reti- 
nal thickness; CRVO = central retinal vein occlusion; ETDRS = Early Treat- 
ment Diabetic Retinopathy Study; FA = fluorescein angiography; IVT- 










t  DISCUSSION 
CENTERA was among the first studies to evaluate IVT-
AFL administered in a treat-and-extend dosing regimen for
the treatment of macular edema secondary to CRVO on a
relatively large scale. 110 AMERICAN JOURNAL OF OPHTThis study showed that IVT-AFL administered in a
reat-and-extend dosing regimen improved functional and
natomic outcomes in patients with macular edema sec-
ndary to CRVO over 76 weeks. Overall, 66% of patients
ained ≥15 letters from baseline to week 76; conversely, the
roportion of patients who achieved a mean treatment in-
erval of ≥8 weeks between the last initiation phase visitHALMOLOGY MONTH 2021 
FIGURE 2. Mean change in BCVA from baseline to week 76. Full analysis set; last observation carried forward. Error bars are 
95% confidence intervals. BCVA = best-corrected visual acuity; ETDRS = Early Treatment Diabetic Retinopathy Study; IVT- 
AF = intravitreal aflibercept; SD = standard deviation. 
FIGURE 3. Mean change in CRT from baseline to week 76. Full analysis set; last observation carried forward. Error bars are 95% 
confidence intervals. Change at week 4, n = 156; n = 157 at week 8; and n = 158 at weeks 24, 52, and 72. CRT = central retinal 



















s  and week 76 did not reach statistical significance. The ro-
bustness of these results was further demonstrated in a sen-
sitivity analysis of the PPS. 
Although fewer than half of patients achieved a mean
treatment interval of ≥8 weeks, post hoc analysis demon-
strated that 63% and 68% of patients achieved a last and
next planned treatment interval of ≥8 weeks, respectively.
Functional and anatomic improvements were achieved
with a mean of 5 injections (baseline to week 24), 4 in-
jections (weeks 24-52), and 3 injections (weeks 52-76). AsVOL. 227 XXXxpected with the treat-and-extend treatment paradigm,
reatment burden was highest during the initiation phase
nd decreased over time. The downward trend in the in-
ensity of the treatment pattern through to the end of the
tudy further supports the notion that a mean treatment in-
erval of ≥8 weeks between the last initiation phase visit
nd week 76 might have been met with the implementa-
ion of a longer observation period. 
Clinically meaningful improvements in BCVA were ob-
erved at all mandatory study visits, with a mean changeXXX 111 
TABLE 2. Safety Overview at Week 76 
Number of patients (%) 
IVT-AFL 
N = 162 
Any AE 134 (82.7) 
Any ocular AE 103 (63.6) 
Any TEAE 131 (80.9) 
Any ocular TEAE 98 (60.5) 
Any ocular TEAE in the study eye 90 (55.6) 
Any ocular TEAE in the fellow eye 56 (34.6) 
Any non-ocular TEAE 106 (65.4) 
Any TEAE related to study drug 6 (3.7) 
Any TEAE related to IVT injection procedure 48 (29.6) 
Any TEAE related to other procedures required by the protocol 10 (6.2) 
Maximum intensity for any TEAE 
Mild 41 (25.3) 
Moderate 70 (43.2) 
Severe 20 (12.3) 
Ocular TEAEs in the study eye ≥5% 
Visual acuity reduced 24 (14.8) 
Increased intraocular pressure 20 (12.3) 
Conjunctival hemorrhage 15 (9.3) 
Retinal ischemia 15 (9.3) 
Macular edema 10 (6.2) 
Foreign body sensation 9 (5.6) 
Retinal hemorrhage 9 (5.6) 
Vitreous detachment 9 (5.6) 
Any SAE 37 (22.8) 
Any treatment-emergent SAE 32 (19.8) 
Any treatment-emergent SAE related to study drug a 2 (1.2) 
Any treatment-emergent SAE related to IVT injection a procedure 2 (1.2) 
Any treatment-emergent SAE causally related to other procedures required by the protocol 0 
Discontinuation of study drug due to AEs 6 (3.7) 
Discontinuation of study drug due to TEAEs 2 (1.2) 
Any APTC event 1 (0.6) 
Any deaths 4 (2.5) 
Any treatment-emergent deaths 2 (1.2) 
a Both cases were related to study drug and IVT injection procedure. 
Safety analysis set. AE = adverse event; APTC = Anti-Platelet Trialists’ Collaboration; IVT = intravitreal; IVT- 



























S  from baseline of + 20 letters at week 76. Results of a
post hoc analysis showed that, by week 76, 67% of pa-
tients had a BCVA of ≥70 letters, which is a thresh-
old for maintaining a driving license in many countries.
Clinically meaningful improvements in anatomic outcomes
were also observed at all mandatory study visits, with a
mean change in CRT of −496 µm at week 76. Most of
the reduction in CRT was seen following the first IVT-
AFL injection ( −462 µm at week 4). It is also worth not-
ing that 73% of patients were treated within 4 weeks of
diagnosis. The safety profile of IVT-AFL was consistent
with that in previous studies. 8 , 9 Notably, there were no
cases of endophthalmitis and only 1 case of intraocular
inflammation. 112 AMERICAN JOURNAL OF OPHTThe functional and anatomic outcomes achieved in
ENTERA using a treat-and-extend regimen are similar
o those seen in other studies of IVT-AFL with monthly
r PRN dosing. 8 , 9 , 12 , 15 The mean change in BCVA from
aseline to week 24 was + 20 letters in CENTERA, + 17 let-
ers in COPERNICUS, 7 + 18 letters in GALILEO, 10 + 19
etters in SCORE-2: Study of COmparative Treatments for
Etinal Vein Occlusion 2, 15 and + 13 letters in LEAVO. 12
he mean change in CRT from baseline to week 52 was
481 µm in CENTERA, −413 µm in COPERNICUS, and
424 µm GALILEO 8 , 9 . 
Most patients in the CENTERA study had nonischemic
RVO (93%). In the COPERNICUS 7 and VIBRANT:








































































real Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in
Patients With Branch Retinal Vein Occlusion 16 studies of
IVT-AFL, a smaller proportion of patients had nonischemic
disease, 67.5% and 60.4%, respectively. In all 3 studies, pa-
tients showed improvements in functional and anatomic
outcomes, therefore indicating that IVT-AFL therapy was
effective in patients with both ischemic and nonischemic
CRVO. 
The importance of differentiating fluid compartments
is gaining increasing attention in neovascular age-related
macular degeneration (nAMD), whereby fluid compart-
ments have been shown to have differential effects on
functional outcomes. 17 It is feasible that tolerance of anti-
VEGF-resistant fluid in specific compartments (such as sub-
retinal fluid) may allow extension of intervals while main-
taining good functional outcomes. However, the impact of
such an approach on the treatment of macular edema sec-
ondary to CRVO has yet to be explored. Additionally, possi-
bly more so than in nAMD, the treatment burden in CRVO
significantly lessens over time as the disease appears to sta-
blize more effectively, potentially enabling further exten-
sion of treatment intervals as the disease stabilizes. 
Further data, including those from the LEAVO study,
suggest that a lower treatment intensity may have a detri-
mental impact on functional outcomes. It is possible that
the lower number of injections through 52 weeks in LEAVO
compared with those in CENTERA (approximately 7.0
vs. 9.2 injections, respectively) allowed for persistent fluid
and more recurrence. Initial monthly dosages for CRVO
may need to be more protracted than the typical treatment
schedule of 3 initial monthly doses in nAMD. 
Published studies, including LEAVO, 12 have also demon-
strated the superior durability of IVT-AFL compared with
ranibizumab, as shown by the lower mean number of injec-
tions over 100 weeks with IVT-AFL (10.0 vs. 11.8 injec-
tions, respectively). However, the vision gains in LEAVO
at 100 weeks ( + 15 letters for IVT-AFL) were not as high
as those reported in CENTERA at 76 weeks ( + 20 letters),
possibly supporting the requirement for proactive treatment
(such as treat-and-extend) in patients with CRVO. VOL. 227 XXXThis study had a number of strengths, including a high
tatistical power of ≥90%, inclusion of a broad range
f baseline visual function (73-24 ETDRS letters; 20/40-
0/320 Snellen equivalent) and early initiation of treat-
ent. Limitations of this study are that it was a single-arm
tudy with no active comparator, thus potentially limiting
nterpretation of the results. However, the single-arm de-
ign was chosen to evaluate the utility of the treat-and-
xtend regimen in patients with CRVO, as this regimen
as not previously been analyzed in large clinical studies
ithin this patient population. Furthermore, analysis of the
ast and next planned treatment intervals was post hoc in
ature, which limited interpretation of the data. 
Overall, clinically meaningful and significant improve-
ents in functional and anatomic outcomes were achieved
ith IVT-AFL administered using a treat-and-extend regi-
en in patients with macular edema secondary to CRVO.
reatment intervals were also extended, and most patients
chieved a last and next planned treatment interval of ≥8
eeks. 
All authors have completed and submitted the ICMJE
orm for Disclosure of Potential Conflicts of Interest and
one were reported. 
TOC 
ENTERA (Evaluation of a Treat and Extend Regimen of
ntravitreal Aflibercept for Macular Edema Secondary to
RVO; NCT02800642) evaluated the efficacy and safety of
ntravitreal aflibercept treat-and-extend dosing in patients
ith macular edema secondary to central retinal vein occlu-
ion. Overall, clinically meaningful improvements in func-
ional and anatomic outcomes were achieved. Treatment
ntervals were extended, and most of the patients achieved
ast and next planned treatment intervals of ≥8 weeks.
hese results support the use of intravitreal aflibercept
reat-and-extend dosing in patients with macular edema in
entral retinal vein occlusion within clinical practice. XXX 113 
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